daniel drucker glp 1 A setback, a lizard and decades of work: The impact of Drucker's research extends far beyond Ozempic How a Canadian scientist and

In the FLOW trial, which enrolled 3533 patients, treatment with Semaglutide (Table 2), a 24% reduction was observed in the urine albumin-to-creatinine ratio, alongside a decreased incidence of acute kidney injury, attenuation of CKD progression and a lower risk of progression to kidney transplantation

So I agree with Fisher that, if safe, the drug could only be used in addition to other skin protection measures

It is fair-balance context, not a buying recommendation, current as of July 2026

Three 20-week double-blind, placebo-controlled studies each with 34-week extensions were conducted to evaluate the efficacy and safety of sitagliptin in 410 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes, with or without insulin therapy (HbA1c 6.5-10% for patients not on insulin, HbA1c 7-10% for patients on insulin)